O
Orbus Therapeutics
Biotech & Life Sciences · Palo Alto, United States · Founded 2012
Orbus Therapeutics is dedicated to developing products that treat rare diseases MoreLess
Orbus Therapeutics is a biopharmaceutical company dedicated to developing innovative therapies for rare diseases, particularly those for which there are few, if any, effective treatments. The company is currently focused on the development and commercialization of eflornithine, a drug aimed at treating recurrent anaplastic astrocytoma, a type of brain cancer. Orbus Therapeutics operates in the niche market of rare diseases, serving patients who are significantly underserved by existing medical treatments. The business model revolves around the research, development, and eventual commercialization of specialized drugs, with revenue generated through the sale of these therapies once they receive regulatory approval. The company is currently in the Phase 3 clinical trial stage for its lead product, eflornithine, and is actively enrolling patients. Orbus Therapeutics aims to improve the health and quality of life for patients facing life-threatening or significantly life-altering diseases.
Keywords: biopharmaceutical, rare diseases, eflornithine, brain cancer, anaplastic astrocytoma, Phase 3 trial, innovative therapies, niche market, underserved patients, commercialization.
Company overview
Orbus Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2012
- Headquarters
- Palo Alto, United States
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 24.3
Valuation & funding
Orbus Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Aug 2020 | $10M | $40M | Undisclosed | — |
| SERIES BOther financing | Aug 2017 | $13M | $50M | Undisclosed | — |
| SERIES AOther financing | Aug 2015 | $33M | $130M | Ernest Mario · Adams Street Partners · H.I.G. HealthBridge · Longitude Capital | — |
Growth signals
Orbus Therapeutics website traffic
Latest recorded traffic for Orbus Therapeutics is 2.9K monthly website visits, up 163.6% over the last three months. Orbus Therapeutics's team declined 50% over the past year.
Comparisons
Orbus Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Orbus Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Orbus Therapeutics has talent and traffic
team presence
In the news
Latest news about Orbus Therapeutics
Recent press, funding announcements, and product moves mentioning Orbus Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Orbus Therapeutics
An AI-synthesized read of the highest-engagement posts about Orbus Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Orbus Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.